Steven Albelda

Professor

University of Pennsylvania
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Steven Albelda is a Professor at the University of Pennsylvania, United States. His research focuses on CAR T cell therapy, particularly in the context of solid tumors, where he explores key lessons to learn and unlearn in the field. His contributions aim to enhance understanding and treatment approaches in immunotherapy.

Articles (35)

Adoptive T-cell therapies have shown limited efficacy against solid tumors, so new approaches are required. In this issue, Chantzoura and colleagues describe MiNK-215, a novel allogeneic fibroblast activation protein–targeting chimeric antigen receptor invariant NK T-cell therapy engineered to secrete IL15. They show that it can remodel the tumor microenvironment and enhance antitumor immunity by depleting fibroblast activation protein–positive cancer-associated fibroblasts and activating multiple immune cell types. In mouse lung tumor and human organoid models, MiNK-215 promotes durable, antigen-specific T-cell responses and overcomes resistance to immunotherapy without causing off-target toxicity. See related article by Chantzoura et al., p. 243

Year:

2026

PD-1 blockade is minimally effective in AB12 and AE17O mouse mesothelioma tumors before or after TI. A, In subcutaneous AB12 mouse mesothelioma tumors, TI significantly decreased the median tumor growth time to 400 mm 3 from 7 days compared with 9 days in untreated TC ( P = 0.025). For TC, n = 17 mice and for TI, n = 11 mice. B, The addition of αPD-1 (TC/αPD-1, dotted black line) to TC did not significantly change tumor response ( P = 0.27). In the TC/αPD-1 group, one mouse was censored because of tumor ulceration and subsequent early euthanasia. For TC/αPD-1, n = 12 mice. C, The addition of αPD-1 to TI led to significantly better outcomes with a slight delay in the median tumor growth time to 400 mm 3 (7 days for TI and 11 days for TI/αPD-1; P = 0.028) For TI/αPD-1, n = 11 mice. D, In AE17O tumors, TI produced a modest insignificant increase in tumor growth compared with TC ( P = 0.057 with a median of 13 days for TI vs. 14 days for TC). For TC, n = 10 mice and for TI, n = 11 mice. E, Adding αPD-1 in AE17O TC mice delayed the median time for tumor growth to 400 mm 3 by 1 week from 14 days in TC mice to 21 days after TC/αPD-1 ( P n = 12 mice. F, The addition of αPD-1 to TI also led to significantly better outcomes with a median time to 400 mm 3 increasing from 13 days after TI to 17 days for TI/αPD-1 ( P n = 12 mice. G and H, In AB12 tumors, flow cytometry of TC and TI tumors found a significant drop in PD-1 levels 2 days after a single αPD-1 dose for ( G ) CD4 + T cells and ( H ) CD8 + T cells. For TC n = 11 tumors, for TC/αPD-1 n = 11 tumors, for TI n = 14 tumors, and for TI/αPD-1 n = 10 tumors. Tumor responses (time to 400 mm 3 ) are compared using a log-rank (Mantel–Cox) test; comparisons of continuous outcomes used a Mann–Whitney test.

Year:

2025

PD-1 blockade significantly decreases tumor growth rates in combination with TI/PDT. αPD-1 initiated 1 hour after PDT and continuing 2× weekly for 3 weeks did not significantly alter tumor growth rates. A, In AB12 mice, more than 50% of both PDT alone ( n = 14) and PDT/aPD-1 ( n = 12) had median survival (time to 400 mm 3 ) greater than 90 days, and no differences between groups were detected ( P = 0.56). B, In AE17O mice, median survivals of 33.5 days for PDT ( n = 34) and 40 days for PDT/αPD-1 ( n = 12) were similar ( P = 0.79). C, In AB12 tumor–bearing mice that received TI prior to PDT, αPD-1 significantly decreased the rate of tumor regrowth ( P = 0.005), with a median survival >90 days for TI/PDT/αPD-1 ( n = 13) and 24-day median survival in TI/PDT ( n = 16). TI/PDT/αPD-1 isotype control ( n = 13) was also significantly different from TI/PDT/αPD-1 ( P = 0.025) and similar to TI/PDT ( P = 0.87). D, In AE17O tumor–bearing mice that received TI prior to PDT, αPD-1 also significantly decreased the rate of tumor regrowth ( P = 0.025), with a median survival of 20.5 days for TI/PDT ( n = 18) and 26 days for TI/PDT/αPD-1 ( n = 20). In all tumor responses, vertical dashes indicate animals that were censored due to tumor ulceration or metastasis. Groups treated with an isotype for αPD-1 are plotted in pale orange. Tumor responses were compared using log-rank (Mantel–Cox) tests.

Year:

2025

PDT decreases PD-L1 expression and significantly reduces tumor growth after TI. TI/PDT-treated mice had significantly longer tumor growth times (to 400 mm 3 ) than TI mice for AB12 ( P A ) and AE17O ( P B ), with medians of 7 days for TI vs. 24 days for TI/PDT for AB12 and 13 days for TI vs. 20.5 days for TI/PDT for AE17O. In AB12 mice, n = 11 for TI and n = 16 for TI/PDT. In AE17O mice, n = 11 for TI and n = 18 for TI/PDT. C, CD11b + Ly6G + cells were significantly increased after TI/PDT ( n = 6) compared with TI ( n = 8) in AB12 tumors ( P P = 0.005). D, Tumors treated with PDT ( n = 6) similarly had increased Ly6G + cells ( P = 0.002) and decreased PD-L1 expression ( P = 0.005) compared with TCs ( n = 7). E, PDT after TI significantly decreased the proportion of Ly6G − cells ( P P = 0.008). F, The proportion of CD11b + Ly6G − cells as a subset of CD45 + immune cells decreased significantly after PDT ( P = 0.001), and their PD-L1 levels were lower on average but not significantly so ( P = 0.073). G, For CD45 − cells, TI/PDT led to a significant drop in the percentage of viable CD45 − cells ( P P = 0.30). H, PDT of CD45 − cells also significantly decreased viability ( P = 0.001), but no significant differences in PD-L1 expression of these cells were observed ( P = 0.29). Representative gates of viable CD45 − cells are shown below for each condition. I, Viable CD45 − cells after TI/PDT had significantly higher levels of PD-L1 than CD45 − cells after PDT alone ( P = 0.004). Tumor responses (growth to 400 mm 3 ) were compared using log-rank (Mantel–Cox) tests, and all other comparisons were made using a Mann–Whitney test. FSC-A, forward scatter area; SSC-A, side scatter area.

Year:

2025

TI upregulates PD-L1 expression on AB12 intratumoral myeloid cells. A, In AB12 tumors, all CD45 − cells, a combination of tumor and stromal cells, were significantly increased in PD-L1 expression 24 hours after TI compared with TC ( P = 0.014). B, For all CD45 + immune cells, PD-L1 levels slightly increased 24 hours after TI compared with TC ( P = 0.054). C, The percentage of intratumoral CD11b + Ly6G + cells (as % of all CD45 + cells) was increased by TI ( P = 0.014); however, changes in the levels of PD-L1 on these cells were not detected. D, The percentage of CD11b + Ly6G − myeloid cells was not significantly changed 24 hours after TI; however, TI tumors had significantly higher PD-L1 expression in this myeloid cell population ( P = 0.021). For all 24-hour data, n = 7 tumors for TC and 8 tumors for TI. E, After 5 days, the numbers of CD11b + Ly6G + cells were about 30% of all CD45 + cells for both TC and TI tumors. At this time point, PD-L1 expression remained unchanged. However, CD62L expression (L-selectin) significantly increased for mice that received TI ( P = 0.007). F, For CD11b + Ly6G − cells, no differences were observed in population numbers or PD-L1 levels. For all 5-day data, n = 8 for TC and n = 8 for TI. Comparisons were made using a Mann–Whitney test. FMO, fluorscence minus one.

Year:

2025

Lung-sparing radical pleurectomy with intraoperative photodynamic therapy (PDT) demonstrates remarkable survival for patients with pleural mesothelioma. Nevertheless, most patients treated with this multimodal approach will develop local tumor recurrence. An understanding of potential causes of treatment failure is central to developing mitigation strategies. Surgery importantly reduces disease burden but also produces tumor-promoting inflammation, as demonstrated through transcriptomic analysis of pleural mesothelioma specimens. Using preclinical models in the setting of combination therapy, we separated the benefit of surgical resection from its counterproductive effects on therapeutic outcome. Specifically, we evaluated mechanisms by which surgically induced inflammation can be therapy-limiting in a murine model of tumor incision (TI) introduced by a surgical cut across the tumor. In this TI model, we identified distinct TI-altered patterns in innate and adaptive inflammatory cells in murine mesothelioma tumors, and we studied changes in these patterns with the addition of PDT. TI introduction of an immunosuppressive environment is established via upregulation of PD-1/PD-L1 expression on tumor cells, T cells, and myeloid cells that is partially resolved by PDT. Immune dysfunction is further mitigated by the addition of PD-1 blockade, leading to curative potential in a process that requires Ly6G + neutrophils and CD8 + T cells. Overall, these studies suggest that, without PDT, surgical modulation of immune cell trafficking and functionality leads to systemic immunosuppression. This immunosuppressive state potentially interferes with the generation of antitumor immunity by PDT. However, targeted inhibition of surgery-induced signaling in the PD-l/PD-L1 pathway counteracts surgery’s immunosuppressive outcomes to enhance PDT efficacy in the intraoperative setting. Significance: Surgery combined with PDT extends survival for patients with mesothelioma, but these patients are still at risk for tumor recurrence, in part due to the immunosuppressive effects of surgery. We find, in a mouse model, that combining surgery, PDT, and immune checkpoint blockade maximizes the efficacy of these therapies.

Year:

2025

Mesothelioma surgery in humans and mice alters immune pathways. A, RNA-seq analysis was performed on tumor tissue isolated over the time course of surgery from 31 patients with PM. Volcano plot of significant gene expression changes associated with time of sample collection showing strength of correlation with time (Spearman rho) and significance of association based on DESeq2 algorithm. FDR P value and/or correlation coefficients highlighted. dn, downregulated; ns, nonsignificant; up, upregulated. B, Analysis of FDR Z -score >2 are shown. The color scale intensity, with red showing activated pathways and blue showing inhibited pathways, indicates significance of enrichment ( P value). Numbers of differentially expressed genes in each pathway are indicated to the right of each bar. C, Heatmap showing log 2 gene expression versus average across tumor specimens for members of the IL-6 and IL-1 families with specimens sorted by the time from initiation of surgery (green bar at the top). Specimens from the same individual patients (uniquely shaped and color-coded) are marked at the time of collection. IL-6 and IL-1 pathways both show increased activity as surgery progresses. D, In the AB12 mouse mesothelioma TI model, IL-1Ra protein levels are higher at 4 hours after TI ( n = 7) compared with samples of untreated TC ( n = 6, Mann–Whitney test P = 0.001).

Year:

2025

Effective PD-1 blockade requires Ly6G + myeloid cells and CD8 + T cells. A, In AB12 tumors, αLy6G initiated 1.5 hours after PDT does not significantly change tumor response ( P = 0.57; PDT/αLy6G shown as dark red dotted line). For PDT, n = 14 and for PDT/αLy6G, n = 13. PDT/αLy6G isotype control ( n = 13) is also not significantly different from PDT/αLy6G ( P = 0.17) or from PDT alone ( P = 0.65). B, In TI/PDT-treated mice, Ly6G depletion did not significantly impact the time for tumors to regrow to 400 mm 3 (TI/PDT/αLy6G, n = 14, shown as pink line) The TI/PDT/αLy6G isotype control group ( n = 14) is similar ( P = 0.81 compared with TI/PDT/αLy6G and P = 0.42 compared with TI/PDT). C, In TI/PDT-treated mice that also received αPD-1, Ly6G depletion led to a rapid and significant decrease in mice with tumors 3 ( P n = 13, shown as dark blue dotted line). The TI/PDT/αPD-1/αLy6G isotype control group ( n = 12) is similar to TI/PDT/αPD-1 ( P = 0.80) and has significantly longer survival than TI/PDT/αPD-1/αLy6G ( P D, Flow cytometric analysis of tumor-infiltrating lymphocytes 1 day after TI/PDT/αPD-1 demonstrated that Ly6G depletion after TI/PDT/αPD-1 did not significantly change the percentage of Ly6C+ cells in the tumor ( P = 0.73, left, n = 7 tumors for TI/PDT/αPD-1 and n = 6 tumors for TI/PDT/αPD-1/αLy6G). However, Ly6G depletion led to a significant increase in the PD-L1 expression on the Ly6C + cells ( P = 0.014, right). E, In AB12 tumors, CD8 depletion (TI/PDT/αPD-1/αCD8, n = 11, shown as pink lines) led to rapid tumor regrowth ( P n = 12) is similar to TI/PDT/αPD-1 ( P = 0.89) and has significantly longer survival than TI/PDT/αPD-1/αCD8 ( P F, Similarly in AE17O tumors, CD8 depletion (TI/PDT/αPD-1/αCD8, n = 10) also led to rapid tumor regrowth ( P = 0.033 compared with TI/PDT/αPD-1). The TI/PDT/αPD-1/αCD8 isotype control group ( n = 10) is similar to TI/PDT/αPD-1 ( P = 0.24) and has significantly longer survival than TI/PDT/αPD-1/αCD8 ( P

Year:

2025

TI increases PD-1 expression on AB12 intratumoral T cells. A, In AB12 tumors, 2 days after TI, the fraction of CD4 and CD8 T cells (as a percentage of all CD3 + cells) was not significantly different between TI ( n = 11) and TC ( n = 14). However, the levels of DX5+ (NKT cells) decreased slightly but significantly in TI ( P = 0.017). B, For all CD3 + cells, the levels of PD-1 were significantly upregulated by TI compared with TC ( P = 0.009). C, For individual T-cell populations, PD-1 was significantly increased in CD8 + ( P = 0.001) and DX5+ ( P = 0.006) T cells after TI compared with TC. D, After 5 days, TC and TI tumors have similar numbers of CD8, CD4, and DX5+ T cells. For CD4 and CD8 T cells, n = 11 for TC and n = 11 for TI. For NKT cells, n = 8 for TI and n = 8 for TC. E, For all CD3 + cells, significant differences in median PD-1 levels were not detected at the 5-day time point ( P = 0.098). F, CD4 + T cells had significantly higher PD-1 expression 5 days after TI ( P = 0.049). Differences in PD-1 expression of CD8 and DX5 T cells at 5 days after TI were small and not statistically significant. Comparisons were made using a Mann–Whitney test. FMO, fluorscence minus one.

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (8)

Gwendolyn Cramer

The Wistar Institute

UNITED STATES
View details

Sandy Widura

The Wistar Institute

UNITED STATES
View details

Andrew Kossenkov

Assistant Professor

The Wistar Institute

UNITED STATES
View details

Sunil Singhal

University of Pennsylvania

UNITED STATES
View details

Theresa M. Busch

University of Pennsylvania

UNITED STATES
View details

Mary E. Putt

Professor

University of Pennsylvania

UNITED STATES
View details

Emmanouil Papasavvas

The Wistar Institute

UNITED STATES
View details

George Georgiou

Professor

University of Texas at Austin

UNITED STATES
View details